A REVIEW OF NEXTSTAGE-SAGA.NET

Apotex alleged that specific US courtroom judgments and FDA selections discriminated towards it, denied it minimum amount normal of procedure and expropriated its investment decision in pravastatin. Damages sought: US$eight million.In January 2011, after protracted proceedings, the tribunal dismissed the maker's claim on jurisdictional grounds and